PROMEDIUS, an AI company focused on aging and metabolic diseases, has signed an AI integration agreement with Siemens Healthineers China on September 18.

Through this collaboration, PROMEDIUS’ chest X-ray–based osteoporosis screening AI software, Osteo Signal, will be integrated into Siemens Healthineers’ research platforms, including AI-Rad Companion Research Frontier and the Syngo.via Frontier Research Platform.

With this integration, Osteo Signal will be introduced to hospital customers in clinical research settings across China via Siemens Healthineers’ research infrastructure.

PROMEDIUS plans to leverage real-world research data and customer feedback to continuously enhance product performance, strengthen the clinical validation of Osteo Signal, and further solidify its global partnership with Siemens Healthineers.

This agreement marks the first step in building an AI-driven preventive healthcare ecosystem powered by Siemens Healthineers’ global infrastructure and PROMEDIUS’ AI technology.

PROMEDIUS will continue advancing Osteo Signal’s capabilities and expanding into global markets as it pursues its mission of “Healthy Aging through AI.”